Tebipenem: Clinical Overview
Tebipenem pivoxil hydrobromide is an oral carbapenem antibiotic indicated for complicated urinary tract infections (cUTI) and acute pyelonephritis, dosed at 600 mg every 8 hours for 7-10 days in adults and children ≥12 years. 1
Indications
Tebipenem pivoxil hydrobromide is specifically indicated for:
- Complicated urinary tract infections (cUTI)
- Acute pyelonephritis
The drug demonstrated non-inferiority to intravenous ertapenem in the ADAPT-PO phase 3 trial, with clinical cure rates of 93.1% versus 93.6% respectively 1. This makes it particularly valuable for step-down therapy from IV carbapenems or as an oral alternative to avoid hospitalization for resistant uropathogens 2, 3.
Key microbiological coverage includes:
- Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales
- Fluoroquinolone-resistant strains
- Multidrug-resistant (MDR) Gram-negative uropathogens 1, 4
Against contemporary US UTI isolates, tebipenem showed MIC90 values of 0.06 μg/mL against Enterobacterales, with 93.7-96.8% susceptibility against ESBL and MDR isolates 4.
Dosing Recommendations
Standard adult dosing (≥12 years):
- 600 mg orally every 8 hours
- Duration: 7-10 days (up to 14 days if bacteremia present) 1
Pediatric considerations:
- Children <12 years: Not approved for use based on current FDA labeling 5
- Investigational pediatric dosing (24-59 months): 4 mg/kg three times daily for shigellosis 6
Pharmacokinetic properties:
- Peak concentration (Cmax) reached within 1.5 hours
- Approximately 55-60% recovered in urine
- Food effect: Comparable absorption in fed and fasted states 7
- Linear, dose-proportional pharmacokinetics from 100-900 mg 7
Important caveat: Renal dosage adjustment will likely be required for patients with altered renal function due to high renal clearance, though specific adjustments are not yet established 2.
Contraindications and Precautions
Expected contraindications (based on carbapenem class):
- Hypersensitivity to carbapenems
- Severe hypersensitivity to other β-lactam antibiotics
Warnings:
- Seizure risk: As with other carbapenems, tebipenem has potential to decrease seizure threshold 2
- Cross-reactivity: Use caution in patients with β-lactam allergies
- C. difficile risk: Monitor for antibiotic-associated diarrhea
Safety profile from clinical trials:
- Adverse events occurred in 25.7% of patients (similar to ertapenem at 25.6%) 1
- Most common: mild diarrhea, headache, and nausea 1, 2
- Generally well tolerated with transient, mild adverse effects 7
Alternative Oral Antibiotics for Resistant UTI Pathogens
When tebipenem is unavailable or contraindicated, consider these alternatives based on susceptibility patterns:
For ESBL-producing organisms:
Nitrofurantoin (for uncomplicated cystitis only, not pyelonephritis)
- 100 mg every 6 hours for 7 days
- Not approved for children <12 years 8
Fosfomycin (single-dose for uncomplicated cystitis)
For fluoroquinolone-susceptible organisms:
- Ciprofloxacin or levofloxacin (with caution due to resistance concerns) 9
Critical limitation: Current oral options show elevated non-susceptibility rates in US hospitals—amoxicillin-clavulanate (26-47%), levofloxacin (45%), and trimethoprim-sulfamethoxazole (41%) in some regions 4. This resistance pattern explains why tebipenem fills a critical gap as the only oral carbapenem option for resistant uropathogens that would otherwise require IV therapy.
When oral options fail:
- IV ertapenem 1 g every 24 hours
- IV meropenem (dosing varies by age/indication) 8
- IV ceftriaxone (for susceptible organisms)
Clinical pearl: Tebipenem's role as an IV-to-oral step-down therapy is particularly valuable—hollow-fiber model studies demonstrate that transitioning from IV ertapenem to oral tebipenem after 1-3 days prevents bacterial regrowth while reducing hospital length of stay 3.